SOD1 and amyotrophic lateral sclerosis: While LCS-1 is a tool compound not in clinical development, the antisense oligonucleotide tofersen, which can mediate the degradation of SOD1 mRNA to reduce SOD1 protein synthesis, is now FDA approved for the treatment of amyotrophic lateral sclerosis.51 These findings highlight the complementarity of the multi-omics approach, as target expression for each drugs was derived from at least one of each omics dataset, and provide a rationale for further pre-clinical and clinical investigation of these compounds in pLGG.